TNF and rheumatoid arthritis: The TARGET (Treatments Against RA and Effect on 18-Fluorodeoxyglucose [18 F-FDG] Positron Emission Tomography [PET]/Computed Tomography [CT]) trial (NCT02374021) seeks to remedy this situation by comparing extent of vascular inflammation in 150 RA subjects with inadequate response to methotrexate randomized to add either a tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab) or sulfasalazine and hydroxychloroquine (HCQ) to the methotrexate [13].